Front-Line Asciminib for Chronic Myeloid Leukemia

Asciminib, a BCR::ABL1 inhibitor, improved responses and lowered toxicity compared with traditional tyrosine kinase inhibitors.

First- and second-generation tyrosine kinase inhibitors (TKIs) targeting the BCR::ABL1 chimeric protein offer durable remission for many patients with chronic myeloid leukemia (CML), but resistance develops in the setting of ATP active-site mutations. Asciminib, a TKI that binds to the ABL myristoyl pocket, is approved for patients with CML that has failed to respond to two prior TKIs due to resistance or treatment intolerance. Investigators now report an industry-sponsored, randomized, phase 3 trial comparing asciminib (80 mg once daily) with investigator's choice of imatinib or a second-generation TKI (nilotinib, dasatinib, or bosutinib) in 405 adults with newly diagnosed chronic-phase CML.

The rate of major molecular response (BCR::ABL1 t…

Reviewing Author

Michael E. Williams, MD, ScM

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee

Michael E. Williams, MD, ScM

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee

Front-Line Asciminib for Chronic Myeloid Leukemia

Topics

Reviewing Author